Quoin Pharma Forms Japan Subsidiary to Advance QRX003 Commercialization
QNRX is trading near its 52-week low of $4.1 (13% above the low) on light trading volume (0.1× avg).
Summary
Quoin Pharmaceuticals has established a wholly-owned subsidiary in Japan to advance the commercial readiness of its lead drug candidate, QRX003, for Netherton Syndrome. This strategic move follows the recent Orphan Drug Designation for QRX003 in Japan on June 4th and positive clinical results reported on June 16th. Japan is a core market for Quoin's self-commercialization strategy, and this subsidiary will facilitate direct engagement with local regulators and stakeholders. For a micro-cap company facing a going concern warning, this represents a critical step towards potential revenue generation from its pipeline. The pivotal Phase 3 study for QRX003 is expected to begin in the second half of 2026, with a potential NDA filing in 2027.
At the time of this announcement, QNRX was trading at $4.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.1M. The 52-week trading range was $4.10 to $41.80. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.